DEFA14A: Sonim Technologies Pivots to DeFi, Raises Capital

Sonim Technologies updates its proxy statement, revealing a strategic pivot to a DeFi business, a capital raise via a convertible note, and an increase in outstanding shares ahead of its Special Meeting.

Summary

• The Special Meeting of Stockholders' record date has been changed from December 2, 2025, to December 17, 2025.
• The number of outstanding common shares has increased from 1,088,635 to 1,488,465 as of the new record date.
• Sonim Technologies acquired 100% of DNA X LLC, a Delaware limited liability company engaged in DNAX DeFi, an advanced on-chain trading protocol, from DNA Holdings Venture, Inc.
• As consideration for DNA X LLC, Sonim issued 223,201 shares of its common stock to DNA Holdings Venture, Inc., representing 19.99% of outstanding shares at issuance.
• Sonim issued a convertible promissory note with a principal amount of $1,200,000 to DNA Holdings Venture, Inc., bearing 10% annual interest and maturing on December 15, 2026, convertible at an initial price of $5.50 per share.
• An exchange agreement was entered into with Streeterville Capital, LLC, converting a $629,640 promissory note into 148,500 shares of common stock at an effective price of $4.24 per share, which is below the Nasdaq Minimum Price.
• The board unanimously recommends voting FOR the Asset Sale Proposal, the Advisory Compensation Proposal, and the Adjournment Proposal at the Special Meeting.
• If the Asset Sale closes around January 31, 2026, the Company estimates Post-Closing Cash of approximately $4 million to $6 million, after paying up to $5.93 million of indebtedness.

Sentiment

Score: 5

Explanation: The filing presents a significant strategic pivot with both potential upside (entry into DeFi) and substantial risks (unproven business, dilution, put option, litigation). The capital raise is positive, but the terms and the speculative nature of the new business create considerable uncertainty, leading to a neutral-to-slightly-negative sentiment due to the high risk profile.

Positives

• Secured $1,200,000 in new capital through a convertible note offering, providing funding for future operations.
• Acquired DNA X LLC, establishing a new 'Successor Business' in the decentralized finance (DeFi) sector, potentially offering a new growth avenue after the divestiture of the Legacy Business.
• The board unanimously supports the Asset Sale and the new strategic direction, indicating internal alignment on the company's future path.

Negatives

• Outstanding shares increased significantly from 1,088,635 to 1,488,465, representing potential dilution for existing shareholders.
• Issued 148,500 shares to Streeterville Capital, LLC at an effective price of $4.24 per share, which is below the Nasdaq Minimum Price, potentially signaling a lower valuation.
• The new 'Successor Business' (DNAX DeFi) is in an incipient stage with virtually no operating history, an unproven business model, and uncertain market acceptance and competitive position.
• DNA Holdings Venture, Inc. holds a put option to repurchase DNA X LLC if specific performance criteria ($600 million aggregate trading volume or $1 million aggregate daily revenues) are not met by June 30, 2026, creating uncertainty about long-term value realization from the new business.
• The convertible note includes a full ratchet price-protection adjustment, which could lead to further dilution if future equity is issued at a lower effective price per share.

Risks

• The Successor Business may not be successfully implemented, may require additional strategic transactions to be viable, and DNA Holdings' option to repurchase DNA X may materially limit the ability to realize any long-term value from the Successor Business following the Asset Sale.
• There is no assurance that the Company will be able to successfully develop, scale, or operate the Successor Business on a profitable or self-sustaining basis, or at all.
• The ability to identify, negotiate, and consummate additional strategic transactions (e.g., acquisitions, joint ventures, capital raising) on acceptable terms or within a timeframe that preserves available cash resources is uncertain.
• Potential for litigation or other disputes related to the Asset Purchase Agreement, including claims related to process or disclosures and investigatory demands under Delaware law, which could delay closing or have a material adverse effect.
• There is no guarantee that the board's determination regarding the use of Post-Closing Cash will align with currently disclosed expectations.
• The DNA Note contains customary events of default and negative covenants that restrict the Company's financial flexibility, including limitations on incurring additional indebtedness, granting liens, amending organizational documents adversely, repurchasing common stock, repaying other indebtedness, or paying cash dividends.

Future Outlook

The Company intends to exit its Legacy Business after the Asset Sale and pivot to the 'Successor Business' of DNAX DeFi, an advanced on-chain trading protocol. The post-closing board will review opportunities for the estimated $4 million to $6 million Post-Closing Cash, including funding the Successor Business, general corporate purposes, or pursuing other strategic transactions. There is no assurance that the Successor Business will be successfully developed or scaled, or that additional strategic transactions will be consummated.

Management Comments

• Our board, upon unanimous recommendation of its Special Committee, determined that the Asset Purchase Agreement and the transactions contemplated thereby, including the Asset Sale, are advisable and in the best interests of the Company and its stockholders and recommends that you vote FOR the Asset Sale Proposal.
• Our board has unanimously determined that the continuation of the Company's business other than the Legacy Business is advisable and in the best interests of the Company and its stockholders and recommends that you vote FOR the Advisory Compensation Proposal and FOR the Adjournment Proposal.

Industry Context

This announcement signifies Sonim Technologies' strategic pivot from its legacy enterprise 5G solutions business into the rapidly evolving decentralized finance (DeFi) sector, specifically focusing on advanced on-chain trading protocols. This move positions the company in a high-growth, yet highly competitive and volatile, segment of the blockchain and cryptocurrency industry, contrasting sharply with its previous hardware-centric operations.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is in receipt of multiple demand letters in connection with the Proxy Statement.
• There is potential for litigation or other disputes related to the Asset Purchase Agreement, including claims related to the Company's process or disclosures and investigatory demands under Delaware law.

Related Party Transactions

• **DNA Holdings Venture, Inc.**: Acquired 100% of DNA X LLC from DNA Holdings Venture, Inc. for 223,201 shares of common stock. Issued a $1,200,000 convertible promissory note to DNA Holdings Venture, Inc. DNA Holdings Venture, Inc. has agreed to a voting arrangement for the Asset Sale and has rights to designate an officer and a board nominee. DNA Holdings Venture, Inc. also holds a put option to repurchase DNA X LLC under certain performance conditions.
• **Streeterville Capital, LLC**: Entered into an exchange agreement to convert a $629,640 promissory note into 148,500 shares of common stock. Streeterville Capital, LLC is also a beneficial owner of 9.98% of the Company's common stock.

Stakeholder Impact

• **Shareholders**: Will vote on the Asset Sale and related proposals. Face significant dilution from recent share issuances (DNA Holdings, Streeterville Capital). Exposed to high risk and uncertainty of the new, unproven DeFi business. Potential for long-term value if the Successor Business is successful, but also risk of loss if it fails or if DNA Holdings exercises its put option.
• **Creditors**: The Company plans to pay up to $5.93 million of indebtedness from Asset Sale proceeds. New debt incurred via the DNA Note ($1.2M). Remaining debt to Streeterville Capital is approximately $2.3M.
• **Management/Board**: Responsible for navigating the strategic pivot, developing the new business, and managing the Post-Closing Cash. DNA Holdings gains influence through board/officer designation rights.

Next Steps

• Stockholders are to vote on the Asset Sale Proposal, Advisory Compensation Proposal, and Adjournment Proposal at the Special Meeting on December 30, 2025.
• The Company's post-closing board of directors will conduct an extensive review of available opportunities for the use of Post-Closing Cash, including funding the Successor Business or pursuing other strategic transactions.
• Financial statements and pro forma financial information related to the acquisition of DNA X LLC will be filed by amendment to the Form 8-K not later than 71 days after the initial Form 8-K filing.

Key Dates

Recommendation

The company is undergoing a radical strategic transformation, divesting its legacy business and acquiring an unproven DeFi venture. While the capital raise and entry into a potentially high-growth sector offer upside, the significant dilution, the speculative nature of the new business, and the explicit risks associated with DNA Holdings' put option introduce substantial uncertainty. Existing shareholders should hold to monitor the execution of the new strategy and the performance of DNAX DeFi, but be prepared for high volatility and potential further dilution. New investors should approach with extreme caution due to the high-risk, speculative nature of the new business and the company's transitional phase.

Keywords

Sonim Technologies, DEFA14A, Proxy Statement, Special Meeting, Asset Sale, DNAX DeFi, DeFi, On-chain trading, Convertible Note, Capital Raise, Stock Dilution, Corporate Governance, Risk Factors, SONM, Blockchain, Fintech